Glaukos, the ophthalmic medical technology company dedicated solely to the transformation of the treatment of glaucoma, is delighted to be attending the Annual Congress in Glasgow in May 2019.
Glaukos has a portfolio of cutting edge products including the revolutionary iStent inject®. Implanted during cataract surgery or as a separate procedure, iStent inject® is the first available ab interno, micro bypass system designed to restore natural physiological outflow through two openings through the trabecular meshwork. The device comprises a unique hand-held injector capable of implanting two .36mm heparin-coated titanium stents via a single corneal entry point.
With more than five years of published efficacy and safety data for the device, clinical studies show that patients experience a reduction in reliance on topical glaucoma medications. iStent inject® was granted NICE approval in 2017.
